DYMO® Partners with ELLKAY to Elevate the Healthcare Community with New Lab Enterprise Platform LKOrbit / The innovative cloud-based connectivity platform will expand outreach, streamline operations and increase revenue.
Today, DYMO®, a leading provider of innovative labeling solutions and part of the Newell Brands global portfolio, announces its partnership with ELLKAY, a nationwide leader in healthcare interoperability for more than 20 years. Through this collaboration, ELLKAY's LKOrbit platform — a lab enterprise solution designed to streamline medical and laboratory workflows — will integrate seamlessly with DYMO's trusted labeling solutions. This partnership provides a comprehensive solution for laboratories and clinics of all sizes, helping them improve efficiency and accuracy in their organizational processes.
'For years, DYMO has been a go-to labeling tool for those in the healthcare field. From quickly and easily creating file folder labels, barcode labels for inventory and specimen tracking and more, we work hand-in-hand with healthcare workers to ensure a seamless and trusted medical environment.' Liesbet De Soomer, Global Marketing Director DYMO at Newell Brands explains. 'We are constantly developing new innovations to help our partners streamline operations and LKOrbit was designed to meet the unique needs of any medical center, whether a large hospital group or a local private practice.'
The LKOrbit Platform was designed to work in conjunction with DYMO's trusted solutions to support both clinical and business needs by eliminating workflow challenges and enabling electronic ordering, including the results of laboratory testing. Key features and platform highlights include:
Demographic, insurance, and clinical data on demand
Patient self-service for both registration and testing
End-to-end orders and results
LOINC, test code and insurance code mapping
Eligibility benefits verification
Automatic state reporting
Secure delivery of results to patients & providers
Surveillance & pooled testing
'ELLKAY is dedicated to supporting healthcare providers with consumer-first innovations', said Ajay Kapare, President & CEO at ELLKAY. 'Our partnership with DYMO allows us to keep delivering cutting-edge communication solutions for healthcare organizations by providing an integrated environment which is able to handle complex orders and live clinical data.'
Learn more at www.ellkay.com/lkorbit.
About ELLKAY:
ELLKAY is a trusted enterprise data management partner, driving innovation and connectivity across the healthcare ecosystem. Since 2002, ELLKAY has empowered hospitals, laboratories, payers, healthcare IT vendors, and more with unmatched data management expertise. With connections to over 58,000 practices and interoperability with 750+ EHR/PM systems across 1,100+ versions, ELLKAY delivers solutions that streamline data exchange, fuel value-based care, and drive smarter decision making. Discover more at ELLKAY.com and connect with us on YouTube, LinkedIn, X/Twitter, or via [email protected].
About DYMO®: DYMO® is a leading global provider of innovative labeling solutions, offering a wide range of products designed to meet the diverse labeling needs of businesses and consumers worldwide.
About Newell Brands:
www.newellbrands.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
DSC® Sponsors the 17th Annual Portland Track Festival
DSC® Showcases DREAMCELL®Insoles, Engineered to Fuel Athlete Performance & Recovery PORTLAND, Ore., June 12, 2025 /PRNewswire/ -- DSC®, a global leader in performance foam manufacturing, proudly continues to sponsor the 17th annual Portland Track Festival. As part of its ongoing commitment to athlete-led innovation, DSC® will provide high-performance insoles to athletes at the premiere two-day event. "This year marks 80 years of innovation at DSC®, and we are honored to support the Portland Track Festival once again," said Johnson Chang, CEO of DSC®. "Our mission has always been to design products that meet athletes' highest performance demands. With our ultra-high performance DREAMCELL® and DURAPONTEX® insoles, we're proud to help athletes power through the finish line—and beyond." At the festival, DSC® will provide athletes with DREAMCELL® PX23 and DURAPONTEX® eN25 —two of the DSC's most advanced materials designed to maximize performance, energy return, and comfort. DREAMCELL® PX23 insole is a high-performance insole material under the popular DREAMCELL® brand. Engineered with advanced, high resilience open-cell PU foam, it delivers an unparalleled 50% performance rebound, superior breathability, and long-lasting comfort—supporting athletes through every stride of their journey. DURAPONTEX® eN25 is a next generation, ultra performance closed-cell foam material developed using DSC's proprietary supercritical fluid foaming technology. Engineered specifically for high-impact, jump-dominant sports, it delivers exceptional durability and ultra-lightweight performance. With 65% resiliency, DURAPONTEX® eN25 offers unmatched rebound to support athletes in achieving peak performance. DSC® was the first brand to utilize supercritical foaming technology in the development of an insole at scale with its DURAPONTEX® N-Series. "We appreciate DSC® continuing to support the Portland Track Festival and their commitment to engage with local athletes," said Michael Bergmann, Board Member and Spokesperson of the Portland Track Festival. "These world-class middle and long-distance athletes offer invaluable feedback that helps DSC® refine and elevate its performance products." DSC® not only supports elite athletes at the Portland Track Festival, but also extends nationwide to running clubs across the U.S. Interested running clubs are invited to partner with DSC's Athlete Engagement Program, to test DSC's advanced insole technologies and provide performance data and feedback that drives the next generation of product development. For 80 years since its founding in 1945, Dahsheng Company (DSC®) has been a leader in foam innovation for the sports industries. Known for its premium comfort and performance foam DREAMCELL® and DURAPONTEX®, DSC® partners with top brands and footwear manufacturers worldwide. By advancing innovation and pushing the limits of foam manufacturing, DSC® is dedicated to creating eco-friendly and advanced foam solutions that set new standards in the industry. Visit to learn more about DSC® and its commitment to sustainability and eco-innovation. Media Contact:Erin Pattersont: +1-323-422-0274e: View original content to download multimedia: SOURCE Dahsheng Chemical Sign in to access your portfolio
Business Wire
4 hours ago
- Business Wire
GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ ® Named Early Access Program (AAC) in France
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has reached agreement with the French medicines safety agency ANSM to consider expeditiously opening the French named early access program (AAC) for LUMEVOQ ® upon approval of a dose-ranging clinical study. Clear Path Forward for LUMEVOQ ® AAC Program in France Following extensive discussions, GenSight reached alignment with ANSM on a plan to open the LUMEVOQ ® AAC program. The agency has agreed that the authorization of a focused dose-ranging study could enable the opening of the early access program. The Company has submitted a preliminary design of the study to the agency and aims to finalize the protocol of a dose-ranging study in Q3 2025. In parallel, the Company will work with the agency to find a solution for patients who may not be included in the study but who may benefit from the AAC program. The AAC program is targeted to open in Q4 2025 at the latest. "In the interest of clearing the way for patients to be treated with LUMEVOQ, we are pleased to have achieved this important agreement with ANSM on a clear path forward for opening patient access to LUMEVOQ in France" said Laurence Rodriguez, Chief Executive Officer of GenSight Biologics."We are thankful for the ANSM's ongoing engagement and openness to discussion, as we work towards the shared goal of providing access to LHON patients who urgently need a safe and effective treatment." Financing Strategy to Support Regulatory Milestones GenSight is implementing a financing strategy to bridge operations through the opening of the AAC program and prepare for the new global Phase III clinical trial. The Company is actively pursuing various funding initiatives to support these critical regulatory milestones. ' We are working on our financing strategy to manage the bridge between now and the opening of the AAC program and the initiation of the Phase III study,' commented Jan Eryk Umiastowski, CFO of GenSight Biologics. "Our focus remains on securing the resources needed to execute our regulatory strategy while exploring additional funding opportunities." Advancing Core Marketing Authorization Strategy In parallel with the French AAC program developments, GenSight will continue to advance its global marketing authorization strategy: Preparation for regulatory consultations in the US and EU Planning for the global Phase III trial scheduled to begin in 2026, designed to meet FDA and EMA requirements Completing the transition to a new manufacturing partner to secure reliable clinical and commercial supply Advancing preparations for MHRA submission in the United Kingdom During this period, the Company will actively pursue additional non-dilutive funding opportunities, including licensing arrangements outside North America and Europe and potential M&A activities. Multiple Value Catalysts GenSight anticipates a number of significant value-creating events in 2025-2026: Financial Position The Company received €0.7 million of its Research Tax Credit (CIR) end of May, with the remaining €0.4 million to be paid in July 2025. Based on current operations and projections, GenSight's cash will support operations until mid-July 2025. The Company acknowledges that current funds are insufficient to cover operational requirements for the next 12 months. The planned financing initiatives are designed to extend the cash runway and enable the initiation of the Phase III clinical trial and UK MHRA marketing application for LUMEVOQ ®. As of June 12, 2025, the number of outstanding GenSight Biologics shares was 131,466,495 ordinary shares. Risk factors Detailed information regarding the Company, including its business, financial information, results, perspectives and related risk factors are contained (i) in the Company's 2024 Universal Registration Document filed with the AMF on April 8, 2025 under number D.25-0234. This document, as well as other regulated information and all of the Company's press releases, can be accessed on the Company's website ( and/or AMF ( The reader's attention is drawn to the risk factors related to the Company and its activities presented in chapter 3 of its 2024 URD in particular the liquidity risk presented in the chapter 3.1.1. About GenSight Biologics GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding product development prospects and financial projections. These statements do not constitute guarantees of future performance and involve risks and uncertainties. While the Company is actively pursuing financing solutions, regulatory requirements necessitate disclosure that material uncertainty exists regarding the Company's ability to continue as a going concern if sufficient funding cannot be secured. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in GenSight Biologics' regulatory filings with the French Autorité des Marchés Financiers. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, GenSight Biologics undertakes no obligation to update or revise the information contained in this press release.
Business Wire
5 hours ago
- Business Wire
Object First Named Immutable Storage Company of the Year and Editor's Choice at Storage Awards
BEVERLY, Mass.--(BUSINESS WIRE)-- Object First, the creator of Ootbi (Out-of-the-Box-Immutability), the ransomware-proof backup storage appliance purpose-built for Veeam ®, was recognized for its innovation and industry leadership with two major honors at the 22nd annual Storage Awards Immutable Storage Company of the Year and Editor's Choice – Company. This is the second consecutive year Object First has been named the Immutable Storage Company of the Year, a category determined entirely by public vote—demonstrating continued trust and validation from the IT and cybersecurity community. Recent research with Enterprise Strategy Group shows that 81% of IT professionals agree that immutable storage built on Zero Trust is an organization's best defense against ransomware. The Editor's Choice – Company award recognizes Object First's growing impact in the backup storage market and its commitment to the channel. 'To be recognized by the public and the editorial community is an incredible honor and speaks to the strength of our product and our growing partner ecosystem,' said Daniel Fried, Senior Vice President of Sales, EMEA, Object First. 'As more organizations prioritize data security, customers and partners turn to immutable backup storage built on Zero Trust principles as the best defense against ransomware. We're committed to delivering the only secure, simple, and powerful backup storage solution purpose-built for the world's leading data resilience platform—Veeam.' Object First's Ootbi appliance makes immutable storage easy to deploy, scale, and manage, with no security expertise required. It is consistently tested for the highest levels of security by third-party organizations like NCC Group, built to follow CISA's Secure by Design principles, and ensures compliance readiness for directives like NIS2. The Storage Awards recognition adds to a year of notable accolades for Object First, including: About Object First Ransomware-proof and immutable out-of-the-box, Ootbi by Object First delivers secure, simple, and powerful backup storage for Veeam ® customers. The appliance can be racked, stacked, and powered in 15 minutes. Ootbi is built on immutable object storage technology designed and optimized for unbeatable backup and recovery performance. Eliminate the need to sacrifice performance and simplicity to meet budget constraints with Ootbi by Object First. To learn more, visit and follow Object First on its blog, LinkedIn, and X. Subscribe to its Zero Gravity podcast here.
